Showing 2151-2160 of 2657 results for "".
- FDA Accepts Tarsus' New Drug Application for TP-03 for Treatment of Demodex Blepharitishttps://modernod.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/As part of its third quarter earnings report, Tarsus Pharmaceuticals announced that the FDA has accepted the company's new drug application (NDA) for TP-03 for the treatment of Demodex blepharitis. The Prescription Drug User Fee Act (PDUFA) target action da
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-announces-positive-results-in-safety-durability-and-biologic-effect-in-oasis-phase-12a-clinical-trial-of-suprachoroidal-cls-ax-in-wet-amd-patients/2481234/Clearside Biomedical announced positive results from its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) patients. Trial results include f
- Verana Health to Present Findings of Studies Using AAO IRIS Registry Data to Advance Insights into Real World Outcomes in Treating AMDhttps://modernod.com/news/verana-health-to-present-findings-of-studies-using-aao-iris-registry-data-to-advance-insights-into-real-world-outcomes-in-treating-amd/2481222/During The Retina Society’s 55th Annual Scientific Meeting Nov. 2-5, Verana Health will present findings on two studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy)
- BioTissue Completes Name Changehttps://modernod.com/news/biotissue-completes-name-change/2481211/BioTissue Holdings announced the completion of its name change from TissueTech. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former Tis
- NIH Scientists Discover Essential Step in Recharging the Eye’s Light-Sensing Retinahttps://modernod.com/news/nih-scientists-discover-essential-step-in-recharging-the-eyes-light-sensing-retina/2481200/Scientists have discovered a mechanism by which an area of a protein shape-shifts to convert vitamin A into a form usable by the eye’s light-sensing photoreceptor cells, according to the National Eye Institute. A previously uncharacterized area of the protein known as RPE65 spontaneously tu
- Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Diseasehttps://modernod.com/news/amydis-awarded-third-grant-from-the-michael-j-fox-foundation-to-support-first-in-human-study-of-a-retinal-tracer-for-parkinsons-disease/2481198/Amydis announced it has been awarded a third grant for $1.5 million from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will support the first-in-human study of a retinal tracer targeting alpha-synuclein (ASYN) in a Prospective Randomized Open, B
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on i
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- UCI Team Demonstrates the Adult Brain has the Potential to Partially Recover from Inherited Blindnesshttps://modernod.com/news/uci-team-demonstrates-the-adult-brain-has-the-potential-to-partially-recover-from-inherited-blindness/2481173/A discovery about how some visually impaired adults could start to see offers a new vision of the brain’s possibilities. The finding that the adult brain has the potential to partially recover from inherited blindness comes from a